ECCV
Eagle Point Credit Company Inc.
There isn't enough reported data to score ECCV yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
ECCV Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| N/A | |
| N/A |
ECCV's revenue and profitability are currently weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like ECCV.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
ECCV PE Valuation
ECCV has no meaningful PE right now: it lost money over the past year.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
ECCV Forward outlook
There aren't enough analyst estimates for ECCV to show an outlook.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
ECCV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.24 | -1227% |
| Q1 2026 | -$1.29 | -$0.89 |
| Q4 2025 | -$0.98 | -217% |
| Q3 2025 | $0.26 | -67% |
| Q2 2025 | $0.11 | -93% |
| Q1 2025 | -$0.40 | -123% |
| Q4 2024 | $0.84 | -50% |
| Q3 2024 | $0.78 | -48% |
ECCV has swung to a loss: it lost $1.24 per share over the past year, after a profit the year before.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over ECCV on earnings quality, reporting a profit while its opponent remains loss making.
ECCV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $31.4M | -45% |
| Q3 2025 | $52M | +10% |
| Q1 2025 | $57.7M | +41% |
| Q4 2024 | $49.5M | +26% |
| Q3 2024 | $47.1M | +31% |
| Q1 2024 | $40.8M | +32% |
| Q4 2023 | $39.4M | +21% |
| Q3 2023 | $36M | +19% |
ECCV's revenue has slid since its 2025 peak: −$63M last quarter, down 188% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -433% | -282 points |
| Q3 2025 | 75% | +1.5 points |
| Q2 2025 | 87% | N/A |
| Q1 2025 | -152% | -220 points |
| Q4 2024 | 65% | -7.4 points |
| Q3 2024 | 73% | +0.9 points |
| Q1 2024 | 69% | -9 points |
| Q4 2023 | 73% | -2.6 points |
ECCV's operating margin was −433% last quarter, down 498 points from the same quarter a year ago, near the bottom of its range since 2019.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over ECCV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
ECCV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $34.8M | +17% |
| Q1 2026 | $29M | +6% |
| Q4 2025 | $30.3M | +24% |
| Q3 2025 | -$16.3M | -158% |
| Q2 2025 | $29.7M | +3.2% |
| Q1 2025 | $27.4M | +24% |
| Q4 2024 | $24.5M | +2% |
| Q3 2024 | $28.2M | +27% |
ECCV has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
ECCV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +480K shares |
| 1 year | +11% | +12.8M shares |
| 3 years | +112% | +70.2M shares |
| 5 years | +286% | +98.5M shares |
| Available history | +390% | +106M shares |
ECCV has 133M diluted shares, up 11% from a year ago, despite $63M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $57.9M |
| Q1 2026 | $4.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ECCV spent $63M buying back its own shares over the past year, after none the year before.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over ECCV on shareholder dilution, with a more favorable share count trend.
ECCV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 7.6x | High |
| Q2 2025 | 4.8x | High |
| Q1 2024 | 1.8x | Healthy |
| Q4 2023 | 1.1x | Healthy |
| Q3 2023 | 1.8x | Healthy |
| Q2 2023 | 1.2x | Healthy |
| Q1 2023 | 2.1x | Moderate |
| Q4 2022 | 1.1x | Healthy |
ECCV's net debt is about 7.6 years of its operating earnings (EBITDA), up from 1.8 years a year ago. Net leverage isn't a meaningful measure for financial services companies like ECCV.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
ECCV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.4 | Neutral |
| Stochastic | 43.3 | Neutral |
ECCV's weekly RSI is 52 (neutral) and its Stochastic is 43 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
ECCV PE vs Financial Services Sector
| Metric | ECCV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
ECCV has no meaningful PE right now: it lost money over the past year.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
ECCV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $24.2 | 0.1% below |
| 20 week MA | $24.1 | 0.2% above |
| 50 week MA | $23.9 | 1.1% above |
| 100 week MA | $23.5 | 2.8% above |
| 200 week MA | $22.9 | 5.6% above |
ECCV has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
ECCV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $24.3 | $21.0 | -13% |
| 2023 | $21.0 | $22.4 | +6.4% |
| 2024 | $22.4 | $22.7 | +1.6% |
| 2025 | $22.7 | $23.5 | +3.5% |
| 2026 YTD | $23.5 | $24.2 | +2.8% |
ECCV has finished higher in three of the last four years. It's up 2.8% so far in 2026.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has the edge over ECCV on returns for 2026, with the stronger performance.